NBIX NEUROCRINE BIOSCIENCES INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 914475 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY38.0%
TTM net income YoY64.1%
TTM EPS YoY60.9%
Revenue 3-yr CAGR27.5%
Net income 3-yr CAGR54.4%
Margins
Gross margin97.8%
Operating margin24.0%
Net margin19.0%
FCF margin28.1%
EBITDA margin24.8%
Returns
ROE20.4%
ROA14.2%
ROIC (approx.)22.7%
Asset turnover0.75x
Leverage & solvency
Liabilities / assets31.1%
Debt / equity0.00x
Current ratio2.04x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.52x
Accruals ratio-7.3%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.12B | $959.00M | $814.50M | $805.50M | $794.90M | $687.50M | $572.60M | $627.70M |
| Cost of revenue | $26.60M | $23.20M | $13.80M | $17.60M | $13.00M | $10.30M | $9.20M | $9.30M |
| Gross profit | $1.10B | $935.80M | $800.70M | $787.90M | $781.90M | $677.20M | $563.40M | $618.40M |
| R&D expense | $351.80M | $326.70M | $296.20M | $258.20M | $250.00M | $244.30M | $263.20M | $185.60M |
| SG&A expense | $366.30M | $439.70M | $318.50M | $301.80M | $291.60M | $286.30M | $276.50M | $287.80M |
| Operating income | $331.30M | $151.50M | $193.40M | $210.90M | $239.00M | $145.60M | $23.60M | $142.00M |
| Interest expense | $300,000 | $2.90M | — | — | $0 | $0 | — | — |
| Pretax income | $283.70M | $162.20M | $246.80M | $239.40M | $291.80M | $159.50M | $14.70M | $162.60M |
| Income tax | $77.20M | $17.80M | $48.90M | $85.70M | $82.30M | $52.00M | $6.80M | $59.50M |
| Net income | $206.50M | $144.40M | $197.90M | $153.70M | $209.50M | $107.50M | $7.90M | $103.10M |
| EBITDA | $340.30M | $159.90M | $200.60M | $217.30M | $245.70M | $151.90M | $30.20M | $148.20M |
| EPS (basic) | 2.03 | 1.43 | 1.97 | — | 2.11 | 1.09 | 0.08 | — |
| EPS (diluted) | 1.96 | 1.39 | 1.91 | — | 2.04 | 1.06 | 0.08 | — |
| Weighted avg. shares (diluted) | 105.20M | 104.20M | 103.40M | — | 102.50M | 101.00M | 102.50M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $641.50M | $332.40M | $266.50M | $713.00M | $340.20M | $264.00M | $194.10M | $241.00M |
| Short-term investments | $96.40M | $57.40M | $1.05B | $767.40M | $774.60M | $711.60M | $749.40M | $843.10M |
| Receivables | $957.30M | $887.00M | $768.10M | $686.80M | $728.00M | $595.70M | $516.00M | $479.10M |
| Inventory | $66.10M | $104.20M | $64.50M | $69.00M | $69.30M | $56.90M | $59.10M | $57.40M |
| Current assets | $2.01B | $1.64B | $2.44B | $2.52B | $2.16B | $1.75B | $1.64B | $1.72B |
| PP&E, net | $92.20M | $90.50M | $90.90M | $89.80M | $97.30M | $91.70M | $87.00M | $82.60M |
| Goodwill | $500.60M | $500.60M | $6.00M | $6.10M | — | — | — | $5.70M |
| Intangibles | $2.19B | $2.23B | — | $4.70M | $35.70M | $37.20M | $36.40M | $36.50M |
| Total assets | $5.63B | $5.36B | $4.91B | $4.63B | $4.27B | $3.89B | $3.69B | $3.72B |
| Current liabilities | $984.60M | $874.50M | $831.70M | $743.40M | $638.00M | $546.30M | $522.90M | $507.70M |
| Total liabilities | $1.75B | $1.67B | $1.50B | $1.38B | $1.26B | $1.20B | $1.15B | $1.13B |
| Shareholders' equity | $3.88B | $3.69B | $3.41B | $3.25B | $3.00B | $2.69B | $2.54B | $2.59B |
| Shares outstanding | 101.30M | 101.60M | 100.60M | 100.10M | 99.70M | 99.00M | 99.00M | 99.40M |
| Cash flow statement | ||||||||
| Operating cash flow | $395.20M | $136.40M | $145.80M | $388.40M | $227.50M | $102.00M | $64.80M | $242.50M |
| Capital expenditure | $11.60M | $7.80M | $9.10M | -$2.40M | $13.20M | $12.50M | $10.70M | $7.30M |
| Free cash flow | $383.60M | $128.60M | $136.70M | $390.80M | $214.30M | $89.50M | $54.10M | $235.20M |
| Investing cash flow | -$11.10M | -$135.40M | -$506.20M | -$52.90M | -$196.70M | -$29.00M | $14.20M | -$68.30M |
| Financing cash flow | -$75.00M | $63.40M | -$86.10M | $37.30M | $45.60M | -$3.30M | -$117.90M | -$290.00M |
| Depreciation & amortization | $9.00M | $8.40M | $7.20M | $6.40M | $6.70M | $6.30M | $6.60M | $6.20M |
| Stock-based compensation | $54.30M | $65.00M | $57.20M | $58.60M | $53.70M | $52.80M | $52.80M | $66.40M |
| Share buybacks | $92.10M | $12.00M | $54.00M | $0 | $0 | $17.70M | $150.00M | $300.00M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.